Last reviewed · How we verify

Acurox 7.5/30 — Competitive Intelligence Brief

Acurox 7.5/30 (Acurox 7.5/30) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combination with abuse-deterrent formulation. Area: Pain Management.

phase 3 Opioid analgesic combination with abuse-deterrent formulation Mu-opioid receptor (oxycodone component) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Acurox 7.5/30 (Acurox 7.5/30) — Acura Pharmaceuticals Inc.. Acurox 7.5/30 is a combination of oxycodone and acetaminophen designed with abuse-deterrent technology to reduce the risk of misuse and overdose.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Acurox 7.5/30 TARGET Acurox 7.5/30 Acura Pharmaceuticals Inc. phase 3 Opioid analgesic combination with abuse-deterrent formulation Mu-opioid receptor (oxycodone component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combination with abuse-deterrent formulation class)

  1. Acura Pharmaceuticals Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acurox 7.5/30 — Competitive Intelligence Brief. https://druglandscape.com/ci/acurox-7-5-30. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: